CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
-2.22%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$5.91M
(+0.55%)
Cap. Flow
+$63.5M
Cap. Flow
% of AUM
5.91%
Top 10 Holdings %
Top 10 Hldgs %
36.46%
Holding
509
New
13
Increased
172
Reduced
270
Closed
23
Top Buys
| 1 |
Apple
AAPL
|
$12.2M |
| 2 |
Amazon
AMZN
|
$8.41M |
| 3 |
Microsoft
MSFT
|
$6.53M |
| 4 |
Analog Devices
ADI
|
$4.63M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
$3.68M |
Top Sells
| 1 |
iShares Silver Trust
SLV
|
$7.9M |
| 2 |
ProShares Ultra Gold
UGL
|
$7.89M |
| 3 |
Arista Networks
ANET
|
$6.7M |
| 4 |
Gilead Sciences
GILD
|
$5.26M |
| 5 |
TSMC
TSM
|
$3.61M |
Sector Composition
| 1 | Technology | 36.93% |
| 2 | Healthcare | 24.36% |
| 3 | Consumer Discretionary | 11.82% |
| 4 | Communication Services | 11.17% |
| 5 | Consumer Staples | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Pacira BioSciences
PCRX
$1.19B
| $231K | 0.02% |
9,282
-508
| -5% | -$12.6K |
|
302
Nike
NKE
$109B
| $229K | 0.02% |
3,559
-14,795
| -81% | -$952K |
|
303
Innoviva
INVA
$1.29B
| $228K | 0.02% |
12,572
-702
| -5% | -$12.7K |
|
304
Aurinia Pharmaceuticals
AUPH
$1.63B
| $221K | 0.02% |
27,548
-2,811
| -9% | -$22.6K |
|
305
Astera Labs
ALAB
$31.8B
| $221K | 0.02% |
3,700
-22,300
| -86% | -$1.33M |
|
306
Adaptive Biotechnologies
ADPT
$1.96B
| $220K | 0.02% |
29,602
-1,690
| -5% | -$12.6K |
|
307
Iovance Biotherapeutics
IOVA
$901M
| $219K | 0.02% |
65,766
+1,141
| +2% | +$3.8K |
|
308
Pulse Biosciences
PLSE
$1.02B
| $218K | 0.02% |
+13,551
| New | +$218K |
|
309
89bio
ETNB
$1.32B
| $213K | 0.02% |
29,282
+4,350
| +17% | +$31.6K |
|
310
Syndax Pharmaceuticals
SNDX
$1.47B
| $210K | 0.02% |
17,121
-978
| -5% | -$12K |
|
311
Structure Therapeutics
GPCR
$1.27B
| $207K | 0.02% |
11,951
-683
| -5% | -$11.8K |
|
312
Novavax
NVAX
$1.28B
| $207K | 0.02% |
32,263
-1,702
| -5% | -$10.9K |
|
313
Geron
GERN
$893M
| $203K | 0.02% |
127,752
-424
| -0.3% | -$674 |
|
314
Spyre Therapeutics
SYRE
$1.03B
| $195K | 0.02% |
12,087
-353
| -3% | -$5.7K |
|
315
Enliven Therapeutics
ELVN
$1.19B
| $193K | 0.02% |
9,800
-560
| -5% | -$11K |
|
316
Harrow
HROW
$1.37B
| $190K | 0.02% |
7,144
-408
| -5% | -$10.9K |
|
317
10x Genomics
TXG
$1.74B
| $190K | 0.02% |
21,712
-975
| -4% | -$8.51K |
|
318
Collegium Pharmaceutical
COLL
$1.21B
| $189K | 0.02% |
6,315
-523
| -8% | -$15.6K |
|
319
Kiniksa Pharmaceuticals
KNSA
$2.65B
| $187K | 0.02% |
8,426
-388
| -4% | -$8.62K |
|
320
Nurix Therapeutics
NRIX
$758M
| $181K | 0.02% |
15,222
+202
| +1% | +$2.4K |
|
321
Veeva Systems
VEEV
$44.7B
| $179K | 0.02% |
771
-5,400
| -88% | -$1.25M |
|
322
Vir Biotechnology
VIR
$732M
| $178K | 0.02% |
27,509
-1,693
| -6% | -$11K |
|
323
Autoliv
ALV
$9.58B
| $177K | 0.02% |
2,000
| – | – |
|
324
Grifois
GRFS
$6.89B
| $174K | 0.02% |
24,470
-1,397
| -5% | -$9.93K |
|
|
GRAL
325
GRAIL, Inc. Common Stock
GRAL
$1.33B
| $172K | 0.02% |
6,740
-385
| -5% | -$9.83K |
|